

Enhancing Predictive Capabilities for ADME-Tox in Drug Discovery through Quantum Artificial Intelligence

Malathi.H¹, Pawan Chaudhary², Ashendra Kumar Saxena³, Esha Ramt⁴

¹Department of Life Sciences, School of Sciences, JAIN (Deemed-to-be University), Karnataka, India

²Maharishi School of Engineering & Technology, Maharishi University of Information Technology, Uttar Pradesh, India,

³College of Computing Science and Information Technology, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh,
India

⁴Department of Biotechnology, Parul University, PO Limda, Vadodara, Gujarat, India

Abstract

The study demonstrates an accurate method for predicting Absorption, Distribution, Metabolism, Excretion and Toxicity (ADME-Tox) features of prospective substances are necessary to progress in drug development. Artificial intelligence (AI) and other cutting-edge technologies are getting more attention as potential means to streamline and enhance ADME and toxicity prediction at the molecular level. Quantum computing has the potential to hasten and reduce the cost of the drug development process by improving high-volume testing methods and the assessment of compound quantities. Chemical/drug ADME-Tox features are evaluated using the proposed method called a Quantum-stimulated Discrete Support Vector Machine (QSDSVM) notation-based string kernel. As a first step, we gathered extensive databases of chemical compounds from reputable sources, together with information on their ADME-Tox characteristics. After data collection, we used the Robust Scaler in the preprocessing phase to reduce the effect of outliers and make the dataset more consistent and stable. Intensive quality checks were performed to clean up the data and make it more reliable. Discriminative elements were extracted from the preprocessed dataset using Linear Discriminate Analysis (LDA). Taking use of the quantum computing paradigm, QSDSVM provides increased computational effectiveness and accuracy for solving difficult ADME-Tox prediction problems. Our model showed remarkable performance indicators by attaining Accuracy (99%), Sensitivity (95%), RMSE (0.349), R² (0.971%) and MAE (0.105) when compared with other traditional methods. The suggested technique demonstrates remarkable accuracy as well as reliability, providing a solid basis for a more effective and trustworthy screening procedure throughout the early phases of drug development.

Keywords: Drug discovery, Artificial Intelligence (AI), Toxicity, Prediction and Quantum computing, Quantum Artificial Intelligence (QAI)

Full-length article *Corresponding Author, e-mail: h.malathi@jainuniversity.ac.in

1. Introduction

Drug usage contenders are absorbed such as Distribution, Metabolism, Excretion and Toxicity (ADME-Tox) qualities, which have a major impact on their effectiveness and safety profiles, must be evaluated as a part of this procedure [1]. The conventional approaches of ADME-Tox prediction can contribute to incorrect predictions at any stage of the drug development process because they fail to capture the complexity of biological systems. A thorough knowledge of compound ADME-Tox qualities is essential in the ever-evolving area of drug discovery, which attempts to identify and create effective therapeutic medicines [2]. Predicting how drug candidate's act in living systems is difficult. Thus, modern technology must be included. Insufficient ADME-Tox prediction using conventional

approaches is a common obstacle in the development of drugs. This study investigates whether incorporating to emerge technologies like quantum computing and artificial intelligence (AI) could improve ADME-Tox's predictive powers [3].

The combination of these technologies holds a great promise for moving beyond the limitations of computational approaches, leading to a more complete and accurate image of how potential drug candidates interact with living organisms [4]. Drug development entails several stages, including target identification, authentication, hit-to-lead maturation, lead refining, molecule identification, assessment and testing humans in the clinic [5]. Quantum artificial intelligence (QAI) combines quantum mechanical theories with machine learning and can be used to approximate

interactions between molecules. To better forecast ADME-Tox outcomes, more precise representation of molecular activity could assist. The study represents attention to their ability to deal with large datasets and intricate interrelationships in molecular structures [6]. Traditional methods for estimating ADME-Tox properties suffer from two main flaws: they oversimplify chemical interactions and we disregard the quantum effects that are crucial in biological systems [7].

Safety concerns in preclinical and clinical stages contribute to drug development failures, with a higher incidence observed in the initial phases. Among safety-related issues, urinary tract toxicity, particularly nephrotoxicity, emerge as a major factor in drug development setbacks [8]. This toxicity impacted the drug candidates at various stages, is linked to the intricate metabolic and excretory functions of the urinary system. Addressing and mitigating these challenges is crucial to enhance the success rates of drug development endeavors [9]. Predictive modeling in the pharmaceutical industry is ripe for disruption and QAI's arrival might be the catalyst for a paradigm shift. Using quantum physics and innovative machine learning (ML) methods, QAI has the ability to expand beyond the confines of conventional computing and provide new light on the complex interaction between chemical structures and biological reactions [10]. This study aims to showcase the feasibility and effectiveness of QSDSVM in predicting chemical/drug ADME-Tox properties. The study [11] presented novel applications of AI in the field of drug discovery. Virtual screening with structures, ligands, library building, high-throughput analysis, reusing old drugs, sensitivity analysis, completely new design, chemical reactions, synthetic accessibility, adverse drug reaction prediction and quantum mechanics are some of the approaches taken to the study of drug discovery. The research looks at the use of AI methods across industries that focus on the intersection between AI and the pharmaceutical industry.

The study [12] examined the wide range of AI approaches used in drug discovery, emphasizing the role played by Artificial Neural Networks (ANNs). They explore how ANN was used to create pharmacological compounds with novel architectures. They investigated complementary AI techniques, such as fundamental computational methods used in software applications. In contrast, the output data refers to the structural geometry peculiar to that of particular molecule. The investigation aims to provide insight into how AI and ANNs, plays a part in the drug molecule design and optimization process, as well as the way that other computational approaches aid in the advancement of the drug discovery process. Important techniques for enhancing predictive models in molecular property prediction were emphasized in this study [13]. These techniques include learned representation, multi-task learning, transfer learning and federated learning. They highlight several under-researched studies, but there are some crucial factors that include dataset quality, benchmarking methods, measuring the efficacy of models and quantifying the certainty with which predictions are made. The research [14] provided the two main types of ADMET prediction methods. They give an organized categorization and description of ADMET prediction databases and software. They discuss some of the well-studied aspects of ADMT, including PBPK modeling and provide a list of relevant applications, a classification

Malathi et al., 2024

scheme and a collection of online resources for making predictions.

The research [15] was to provide the theoretical framework for applying computational approaches into pharmacologic investigations at various stages of the drug development process. By screening millions of potential molecules in a computer, in silico approaches that speed up the process. Both ligand-based and structure-based virtual screening influences the drug development by identifying compounds with a high probability of binding to receptors. The goal of the Quantitative Structure-Activity Relationship (QSAR) and the Quantitative Structure-Property Relationship (QSPR) methods is to employ mathematical algorithms to predict chemical characteristics interred in descriptors, which are chemical properties influencing observable reactions. These techniques are crucial for improving medication development of efficacy and productivity. The study [16] provided a few-shot learning and its implications for the pharmaceutical industry. The research demonstrated versatility, few-shot education can find applications in diverse domains, such as identifying novel drug targets, forecasting drug effects and crafting compounds with specific biological effects. Its adaptability extends its potential impact across various drug discoveries and development settings. The research provided an important takeaway on the viability coupled with the potential of few-shot learning in key drug discovery and development areas.

Diverse research findings contribute to a thorough understanding of this innovative approach with potential applications. The timeline of drug research as well as development, drug design methodologies and the involvement of AI in the drug discovery process was addressed extensively. Both machine learning (ML) and deep learning (DL), two innovative techniques, are extensively analyzed. The medical field has been impacted by big data analysis, as seen by the case studies presented [17]. Because so much of information exists about possible new medication, the drug discovery process has entered the big data paradigm. The development of new AI techniques for implementing unique models in response to the dynamic, heterogeneous and large pharmacological datasets is at the core of this shift. Modern AI methods, such as deep learning (DL) and pertinent modeling studies provide novel techniques for assessing drug candidates' effectiveness include safety using big data modeling along with analysis [18].

1.1. Key Contribution

- The research indicates that QAI approaches represent paradigm advancement in ADME-Tox prediction, providing up the possibility y to more accurate, cost-effective and time-efficient drug development procedures that could change the drug industry as we recognize it.
- This paper presents a quantum-inspired technique, the QSDSVM, demonstrating how quantum computing has the potential to improve the accuracy and efficiency of ADME-Tox prediction in drug development.
- Utilizing current approaches such as Robust Scaler normalization and LDA for feature extraction, the research boosts the accuracy of defining chemical/drug characteristics, leading to more dependable predictions in toxicity assessment.

- The QSDSVM assessment shows impressive performance measures, such as a high Accuracy of 99%, Sensitivity of 95% and low RMSE, R² and MAE values, proving its resilience coupled with efficacy in predicting ADME-Tox features.

2. Methodology

The approach integrates preprocessing methods like Robust Scaler normalization and LDA for feature extraction with a string kernel based on the QSDSVM paradigm. Optimizing tasks using quantum algorithms allows for more accurate ADME-Tox prediction by better managing complicated datasets and capturing subtle correlations between characteristics. Fig. 1 depicts suggested methods.

2.1. Dataset

Multitask Graph Attention (MGA) for making the most of existing toxicity data. MGA allows for regression and classification in toxicity prediction simultaneously. MGA is a possible approach for improving the quality of toxicity data by making optimal use of existing information, therefore resolving problems related to limited data in toxicity prediction [19]. To evaluate MGAs data usage skills, compare the predictions of 31 toxicity datasets using single-task and multitask techniques. On 17 of the 18 tasks examined that the multi-task predictions showed considerable improvement over the single-task predictions, whereas on the remaining task, the multitask predictions fared poorly.

2.2. Data preprocessing using robust scaler

The Robust Scaler distinguishes itself by adopting a novel method that deviates from traditional scaling approaches. Conventional methods using the min-max range, this scaler employs the interquartile range (IQR) that enhances resilience against outliers. During scaling, the Robust Scaler excludes the median and adjusts data based on the IQR, which represents the span between the first quartile (25th quantile) and the third quartile (75th quantile). It is denoted as $[[IQR]]_{(1,3)}(X)$, this robust scaling technique captures data that spreads in the inter-quartile range, making it strong in scenarios where outliers can distort the scaling process. This statistical measure provides insight into the dispersion of values in the central 50% of the data distribution, which offers a robust indication of variability while mitigating the influence of extreme importance in Equation (1).

$$RS(X_i) = \frac{(X_i - \text{median}(X))}{IQR_{1,3}(X)} \quad (1)$$

2.3. Feature extraction using Linear discriminate analysis (LDA)

A LDA reduces the complexity of the problems, which increases the generalizability of the mean classifier and reduces the processing time, as described in Equation (2). The transformation matrix S_6 transforms a map from a d-dimensional input space F^G to an m-dimensional aspect space F^N .

$$V: L^s \rightarrow L^m m < s \quad (2)$$

The LDA can eliminate features by linearly translating the production space into the participation space.

Both classifiers are constructed similarly, with minor exception towards the end. The dimension d within-class covariance square matrix is defined by the following formula W_c in Equation (3-9)

$$U_v = \frac{1}{n} \sum_{j=1}^2 \sum_{i=1}^{m_j} [(Z_i)_j - m_j] [(Z_i)_j - m_j]^c \quad (3)$$

When the class i denotes a signaling vector, n_i is available. When tagging an event, information is divided into non-occurrence zones and occurrence areas.

$$C_o = \frac{n_1}{n} (m_1 - m)(m_1 - m)^c + \frac{n_2}{n} (m_2 - m)(m_2 - m)^c \quad (4)$$

The whole set of parameters is represented by the vector m . LDA seeks a $V * m$ transformation matrix G that equalizes the variance across classes while maximizing the variation between categories.

$$W_o = \frac{m_1 m_2}{m^2} (n_2 - n_1)(n_2 - n_1)^V \quad (5)$$

Due to its reliance on one vector $(n_2 - n_1)$, C_B has rank 1. Furthermore, the level of $V_U^{-1} C_B$ is equivalent to one person, even if W_c has an inhabited group. There is a single nonzero eigen-value.

$$P_1 = \frac{U_V^{-1}(m_2 - m_1)}{\|U_V^{-1}(m_2 - m_1)\|} \quad (6)$$

The mapping function creates the output vector U and the eigenvector has the capability of a vector $m_2 - m_1$ as well as requires a single property.

$$H = E_1^c H = (m_2 - m_1)^c U_V^{-1} \quad (7)$$

Equation (9) illustrates the action of generic function. Due to the correlation component W_c^{-1} not included, the process can be expressed as follows.

$$W = AZ = U(m_2 - m_1)^t Z \quad (8)$$

However, there must be LDA classification before inverting the covariance matrix t_z which yields an unconditioned matrix.

$$U_{vl} = U_V + \delta I \quad (9)$$

The dominance of a single large numerical feature in an analysis or model can be avoided by ensuring that the characteristics are of the same size. Normalization assists with extremes and makes the data more consistent, both of which are important for distance-based algorithms. In this case, the classification approach is known as a regularized LDA.

2.4. Predictive model for Quantum Stimulated Discrete Support Vector Machine (QSDSVM)

We present the primary algorithm 1, similar to classical SVMs, which performs classification. It's crucial to note that actual computations occur upon the calculate expression to preserve the exponential-speedup advantage for operations on extensive vectors or matrices. For the interim, γ is considered as ∞ .

Algorithm 1 QSDSVM

Input: n training data points and their labels $\{(w_{i,z_i}): w_i \in \mathbb{R}^m, z_i = \pm 1\}$ ($i=1, \dots, n$). Where $z_i = \pm 1$ depending on the class to which w_i belongs. Error bound ϵ and belongs. Error bound $1-\eta, \gamma$ set as ∞

Find α that $\|\alpha' - \alpha\| \leq \epsilon \|\alpha\|$ with success probability at least $1 - \eta$, in which $\alpha = [(W^T S W)]^{(+)} z$

For any given $w \in \mathbb{R}^m$, find its class.

In it: Set q, d

Sample columns: Sample q column indices j_1, j_2, \dots, j_q

According to the column norm squares $(\|W_{(:,j)}\|)^2 / \sum_{j=1}^q \|W_{(:,j)}\|^2$

Define 'W' to be the matrix whose s th column is

$(\|W_{(:,j)}\| / \sqrt{q}) (\|W_{(:,j)}\| / \|W_{(:,j)}\|)$ Define $B = [W]^T S W$

Sample rows: $t \in [q]$ uniformly, and then sample a row index i distributed as $(\|W_{(i,:)}\|^2 / \sum_{t=1}^q \|W_{(t,:)}\|^2)$ Sample a total number of d row indices i_1, i_2, \dots, i_d this way. Define W'' whose q th row is

$(\|W_{(i,:)}\| / \sqrt{d}) (W_{(i,:)} / \|W_{(i,:)}\|)$ Define $B'' = [W'']^T S W''$

Spectral decomposition: Calculate the spectral decomposition of B'' Denote here by $B'' = U'' \Sigma'' U''^T$ $[W'']^T S W''$ Denote the calculated eigenvalues by $\sigma_k, k=1, \dots, l$

Approximate eigenvectors: Let $Q = [W']^T S W$. Define $U'_k = (Q^T S U_k) / \sigma_k, k=1, \dots, l, U' = [U'_k]_{k=1}^l$

Estimate matrix elements: Calculate $\lambda'_k = U'_k{}^T S Z$ to precision $(3\epsilon / (16\sqrt{K})) \|z\|$ by $1 - (\eta/4)$ Let $v = \sum_{k=1}^l \lambda'_k U_k$

Find query access: Find query access of $\alpha' = L^T S v$ by $\alpha'_o = U^T O'(*, o)$ in which Q'_{ji} is calculated to precision ϵ by Algorithm 1, each with success probability $1 - (\eta/4) [864/\epsilon^2 \log_{10}(8/\eta)]$

Find sign: Calculate $w^T S W \alpha'$ to precision $(\epsilon/4) \|\alpha'\|$ with success probability $1 - (\eta/4)$ Output: The answer class depends on the sign. Positive corresponds to 1 while negative to -1. Theorem 1 given parameters $\epsilon > 0, 0 < \eta < 1$ and given the data matrix w with size $n \times m$, rank l norm 1, and Condition number l , the quantum-inspired SVM algorithm will find the classification expression $w^T S W \alpha$ for any vector $w \in \mathbb{C}^m$ find the classification expression ϵ by Algorithm 1, each with success probability higher than $1 - \eta$, and time complexity $S(n, m, l, \epsilon, \eta)$.

3. Results

The effectiveness of the proposed models in predicting abilities for ADME-Tox in Drug Discovery that assessed through metrics like R-squared (R^2), Mean Absolute Error (MAE) as well as Root Mean Square Error (RMSE), the evaluation includes the application of various ML methods, such as XGBoost [20], RRF [20], rbfRVM [20] and QSDSVM, on an identical dataset. The comparison aims to gauge the performance of these models and their computational efficiency in predicting abilities for ADME-Tox in drug discovery.

3.1. RMSE

Error calculated as the root mean square is an abbreviated RMSE. In regression tasks, one common statistic

is the mean deviation between model predictions and the observed data. Models that predict continuous numerical values can measure their efficacy using RMSE Equation (10).

$$RMSE = \sqrt{\frac{1}{n} * \sum(\text{predicted}_i - \text{actual}_i)^2} \quad (10)$$

Fig. 2 and (Table 1) present the outcomes of a comparative analysis between the RMSE values derived from the novel methodology and those obtained using the existing method. Compared to the current study results, the new approach achieves XGBoost (0.412), RRF (0.557), rbfRVM (0.448) and QSDSVM (0.349). The cost of our technique is less than the current alternatives. This demonstrates that the QSDSVM is effective than other methods for error evaluation, fault diagnosis and adaptive correction.

3.2. MAE

MAE is used in statistics and ML to measure the typical size of mistakes made while making predictions. The MAE compares the expected and observed values without considering the nature of the errors. In regression tasks; one common statistic is the mean absolute deviation between the model predictions and the observed values. Model predictive abilities for continuous numerical values can be evaluated with particular utility of MAE using Equation (11).

$$MAE = \left(\frac{1}{n}\right) * \sum(|\text{predicted}_i - \text{actual}_i|) \quad (11)$$

The MAE of the suggested technique and the standard method are compared in Fig. 3, (Table 2), respectively. In comparison, the MAE values for the defined processes of employing XGBoost (0.318), RRF (0.192), rbfRVM (0.364) and QSDSVM (0.105), respectively. These values are lower than the other existing methods. This indicates that our proposed strategy is more effective for error evaluation, fault diagnosis and adaptive correction.

3.3. R²

R^2 is a statistical measure for assessing the extent to which a regression model independent (predictor) variables that explain the variance in the dependent (outcome) variable. The R^2 value of a model using regression is a measure of the model's accuracy in predicting the desired variable. Fig. 4, (Table 3) analyze the R^2 values obtained from the recommended and conventional methodologies, respectively. Contrast with existing method for the R^2 values of XGBoost for (0.775), RRF for (0.957), rbfRVM (0.948) and QSDSVM for (0.971). The proposed QSDSVM algorithms have a lower R^2 value than the standard methods presently in use. This demonstrates that the proposed strategy is superior for detecting errors determining their root causes and making timely corrections.

3.4. Accuracy

Accuracy is used as a metric of how ML models perform on categorization tasks. By comparing the actual labels with the desired ones in the input data, it provides a quantitative measure of the model predictive efficacy.




Figure 1. Proposed methodology (Source: Author)




Figure 2. Comparison of RMSE (Source: Author)




Figure 3. Comparison of MAE (Source: Author)




Figure 4. Comparison of R²(Source: Author)




Figure 5. Comparison of Accuracy (Source: Author)




Figure 6. Comparison of sensitivity (Source: Author)

Table 1. Result of RMSE (Source: Author)

Methods	RMSE
XGBoost [20]	0.412
RRF [20]	0.557
rbfRVM [20]	0.448
QSDSVM [Proposed]	0.349

Table 2. Result of MAE (Source: Author)

Methods	MAE
XGBoost [20]	318
RRF [20]	192
rbfRVM [20]	364
QSDSVM [Proposed]	105

Table 3. Result of R²(Source: Author)

Methods	R2 (%)
XGBoost [20]	775
RRF [20]	957
rbfRVM [20]	948
QSDSVM [Proposed]	971

Table 4. Result of Accuracy (Source: Author)

Methods	Accuracy (%)
XGBoost [20]	86
RRF [20]	91
rbfRVM [20]	97
QSDSVM [Proposed]	99

Table 5. Result of sensitivity (Source: Author)

Methods	Sensitivity (%)
XGBoost [20]	87
RRF [20]	91
rbfRVM [20]	93
QSDSVM [Proposed]	95

Accuracy is determined by the ratio of correct predictions to the total number of forecasts, providing a direct metric for evaluating the overall effectiveness in categorizing data.

$$\text{Accuracy} = \frac{\text{TN} + \text{TP}}{\text{TN} + \text{TP} + \text{FN} + \text{FP}} \quad (12)$$

Fig. 5 illustrates the superior accuracy of our proposed method compared to contemporary techniques. The RSO-ARBA outperforms modern algorithms like XGBoost (0.86%), RRF (0.91%) and rbfRVM (0.97%). Table 4 provides a short description of the many ways in which the QSDSVM (0.99%) model excels in data categorization, demonstrating its superiority to other existing methods.

3.5. Sensitivity

The proposed model's sensitivity depends on its ability to isolate each informative subset of a dataset. It can be estimated by dividing the fraction of true positive (TP) rate by the total number of TPs and false positive (FP) rate. The sensitivity is calculated using Equation (13).

$$\text{sensitivity} = \frac{\text{TP}}{\text{TP} + \text{FN}} \quad (13)$$

Sensitivity evaluations of classical models and the QSDSVM technique are shown in Fig. 6. Regarding sensitivity, the QSDSVM approach is superior to other existing methods, as shown in (Table 5). The maximum sensitivity for the XGBoost is 0.87%, RRF (0.91%) and rbfRVM (0.93%). However, the proposed QSDSVM system yielded excellent results, with a sensitivity value of (0.95%).

4. Conclusion

This research introduces the QSDSVM method as a revolutionary approach for enhancing the prediction of chemical/drug ADME-Tox properties in drug discovery. QAI techniques, particularly quantum algorithms, the proposed QSDSVM demonstrates remarkable accuracy (99%), sensitivity (95%) and performance metrics, including low level of RMSE (0.349) and high level of R^2 (0.971%). The model demonstrates its potential for streamlining drug development using modern technologies, including AI, Robust Scaler normalization and LDA for feature extraction. This study describes the revolutionary impact that quantum computing having on predictive modeling in the pharmaceutical industry, leading to a more precise and productive research environment. The integration of QAI techniques holds promise for addressing resource-intensive challenges in ADME-Tox prediction, fostering a new era of informed and accelerated drug development. The study's emphasis on hardware-constrained quantum computing simulations can lead to inconsistencies between the results obtained and those obtained with more advanced quantum computers in the future.

References

- [1] N.E.H. Daoud, P. Borah, P.K. Deb, K.N. Venugopala, W. Hourani, M. Alzweiri, V. Tiwari. (2021). ADMET profiling in drug discovery and development: perspectives of in silico, in vitro and integrated approaches. *Current Drug Metabolism*. 22(7): 503-522.
- [2] M.A. Lim, S. Yang, H. Mai, A.C. Cheng. (2022). Exploring deep learning of quantum chemical properties for absorption, distribution, metabolism, and excretion predictions. *Journal of Chemical Information and Modeling*. 62(24): 6336-6341.
- [3] S. Kar, J. Leszczynski. (2020). Open access in silico tools to predict the ADMET profiling of drug candidates. *Expert Opinion on Drug Discovery*. 15(12): 1473-1487.
- [4] C.S. Tautermann. (2020). Current and future challenges in modern drug discovery. *Quantum Mechanics in Drug Discovery*. 1-17.
- [5] J. Peña-Guerrero, P.A. Nguewa, A.T. García-Sosa. (2021). Machine learning, artificial intelligence, and data science break into drug design and neglected diseases. *Wiley Interdisciplinary: Computational Molecular Science*. 11(5): e1513.
- [6] V. Gallego, R. Naveiro, C. Roca, Rios D. Insua, N.E. Campillo. (2021). AI in drug development: a multidisciplinary perspective. *Molecular Diversity*. 25: 1461-1479.
- [7] F.I. Saldívar-González, V.D. Aldas-Bulos, J.L. Medina-Franco, F. Plisson. (2022). Natural product drug discovery in the artificial intelligence era. *Chemical Science*. 13(6): 1526-1546.
- [8] O. Daoui, S. Elkhatabi, S. Chtita. (2023). Design and prediction of ADME/Tox properties of novel magnolol derivatives as anticancer agents for NSCLC using 3D-QSAR, molecular docking, MOLCAD, and MM-GBSA studies. *Letters in Drug Design & Discovery*. 20(5): 545-569.
- [9] Y. Zhang, L. Xie, D. Zhang, X. Xu, L. Xu. (2023). Application of Machine Learning Methods to Predict the Air Half-Lives of Persistent Organic Pollutants. *Molecules*. 28(22): 7457.
- [10] H. Zhou, M. Shan, L.P. Qin, G. Cheng. (2023). Reliable prediction of cannabinoid receptor two ligands by machine learning based on combined fingerprints. *Computers in Biology and Medicine*. 152: 106379.
- [11] C. Muller, O. Rabal, C. Diaz Gonzalez. (2022). Artificial intelligence, machine learning, and deep learning in real-life drug design cases. *Artificial Intelligence in Drug Design*. 383-407.
- [12] H. Bohr. (2020). Drug discovery and molecular modeling using artificial intelligence. In *Artificial Intelligence in Healthcare*. 61-83.
- [13] J. Shen, C.A. Nicolaou. (2019). Molecular property prediction: recent trends in the era of artificial intelligence. *Drug Discovery Today: Technologies*. 32: 29-36.
- [14] F. Wu, Y. Zhou, L. Li, X. Shen, G. Chen, X. Wang, Z. Huang. (2020). Computational approaches in preclinical studies on drug discovery and development. *Frontiers in chemistry*. 8: 726.
- [15] A. Hamidović, E. Hasković, S. Muhić, M. Planinić, N. Omerović, S. Škrbo. (2021). Application of in silico methods in pharmacokinetic studies during drug development. In *International Conference on Medical and Biological Engineering*. 499-510.
- [16] S.S. Mendonça, A.R. de Sousa Vitória, T.W. de Lima, A.R. GalvãoFilho, C.H. Andrade. (2023).

- Exploring new horizons: Empowering computer-assisted drug design with few-shot learning. *Artificial Intelligence in the Life Sciences*. 100086.
- [17] P. Pasrija, P. Jha, P. Upadhyaya, M. Khan, M. Chopra. (2022). Machine Learning and Artificial Intelligence: A Paradigm Shift in Big Data-Driven Drug Design and Discovery. *Current Topics in Medicinal Chemistry*. 22(20): 1692-1727.
- [18] Y. Takada, K. Kaneko. (2023). Automated machine learning approach for developing a quantitative structure–activity relationship model for cardiac steroid inhibition of Na⁺/K⁺-ATPase. *Pharmacological Reports*. 1-9.
- [19] Z. Wu, D. Jiang, J. Wang, C. Y. Hsieh, D. Cao, T. Hou. (2021). Mining toxicity information from large amounts of toxicity data. *Journal of Medicinal Chemistry*. 64(10): 6924-6936.
- [20] B. Mazumdar, P.K.D. Sarma, H.J. Mahanta. (2023). Predicting Renal Toxicity of Compounds with Deep Learning and Machine Learning Methods. *SN Computer Science*. 4(6): 812